Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment

Brian Morse, Daniel Jeong, Gary Ihnat, Alvin C Silva

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.

Original languageEnglish (US)
JournalAbdominal Radiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Clinical Trials
Guidelines
Response Evaluation Criteria in Solid Tumors
Neoplasms
Radiologists

Keywords

  • Non-target lesion
  • RECIST v1.1
  • Response assessment
  • Target lesion

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment. / Morse, Brian; Jeong, Daniel; Ihnat, Gary; Silva, Alvin C.

In: Abdominal Radiology, 01.01.2018.

Research output: Contribution to journalArticle

@article{14d35a7a209942618301f74314a68830,
title = "Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment",
abstract = "Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.",
keywords = "Non-target lesion, RECIST v1.1, Response assessment, Target lesion",
author = "Brian Morse and Daniel Jeong and Gary Ihnat and Silva, {Alvin C}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00261-018-1752-4",
language = "English (US)",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",

}

TY - JOUR

T1 - Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment

AU - Morse, Brian

AU - Jeong, Daniel

AU - Ihnat, Gary

AU - Silva, Alvin C

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.

AB - Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.

KW - Non-target lesion

KW - RECIST v1.1

KW - Response assessment

KW - Target lesion

UR - http://www.scopus.com/inward/record.url?scp=85053323384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053323384&partnerID=8YFLogxK

U2 - 10.1007/s00261-018-1752-4

DO - 10.1007/s00261-018-1752-4

M3 - Article

C2 - 30196362

AN - SCOPUS:85053323384

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

ER -